LongBio Ends Stabilization; Over-Allotment Option Fully Exercised for 2.13 Million H Shares at HK$96.06

Bulletin Express07-02

LongBio Pharma (Suzhou) Co., Ltd. (LONGBIO-B) announced the completion of the 30-day post-listing stabilization period for its Global Offering, which concluded on 2 July 2026. During this window, Sinolink Securities (Hong Kong) Company Limited, acting as Stabilizing Manager, executed two key actions:

1. Overallocation • 2.13 million H Shares were over-allocated in the International Offering, equivalent to approximately 15% of the 14.19 million Offer Shares initially available under the Global Offering.

2. Full exercise of the Over-allotment Option • On 30 June 2026, the Sole Sponsor-Overall Coordinator fully exercised the Over-allotment Option for the same 2.13 million H Shares. • The shares were issued at the Offer Price of HK$96.06 per H Share, excluding related transaction costs (1.00% brokerage, 0.0027% SFC levy, 0.00565% Stock Exchange fee, and 0.00015% AFRC levy). • The issuance facilitated timely delivery to investors who had agreed to delayed settlement under the Global Offering.

No market purchases or sales of LongBio’s H Shares were conducted for stabilization purposes during the period.

The company’s board, chaired by Executive Director Dr. Liu Heng, confirmed that the stabilization measures have now concluded.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189095400?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 18:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189095400","market":"us","top_or_hot":-1,"title":"LongBio Ends Stabilization; Over-Allotment Option Fully Exercised for 2.13 Million H Shares at HK$96.06","media":"Bulletin Express","content":"<p>LongBio Pharma (Suzhou) Co., Ltd. (LONGBIO-B) announced the completion of the 30-day post-listing stabilization period for its Global Offering, which concluded on 2 July 2026. During this window, Sinolink Securities (Hong Kong) Company Limited, acting as Stabilizing Manager, executed two key actions:</p>\n<p>1. Overallocation  \n   • 2.13 million H Shares were over-allocated in the International Offering, equivalent to approximately 15% of the 14.19 million Offer Shares initially available under the Global Offering.</p>\n<p>2. Full exercise of the Over-allotment Option  \n   • On 30 June 2026, the Sole Sponsor-Overall Coordinator fully exercised the Over-allotment Option for the same 2.13 million H Shares.  \n   • The shares were issued at the Offer Price of HK$96.06 per H Share, excluding related transaction costs (1.00% brokerage, 0.0027% SFC levy, 0.00565% Stock Exchange fee, and 0.00015% AFRC levy).  \n   • The issuance facilitated timely delivery to investors who had agreed to delayed settlement under the Global Offering.</p>\n<p>No market purchases or sales of LongBio’s H Shares were conducted for stabilization purposes during the period.</p>\n<p>The company’s board, chaired by Executive Director Dr. Liu Heng, confirmed that the stabilization measures have now concluded.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LongBio Ends Stabilization; Over-Allotment Option Fully Exercised for 2.13 Million H Shares at HK$96.06</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongBio Ends Stabilization; Over-Allotment Option Fully Exercised for 2.13 Million H Shares at HK$96.06\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-02 18:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LongBio Pharma (Suzhou) Co., Ltd. (LONGBIO-B) announced the completion of the 30-day post-listing stabilization period for its Global Offering, which concluded on 2 July 2026. During this window, Sinolink Securities (Hong Kong) Company Limited, acting as Stabilizing Manager, executed two key actions:</p>\n<p>1. Overallocation  \n   • 2.13 million H Shares were over-allocated in the International Offering, equivalent to approximately 15% of the 14.19 million Offer Shares initially available under the Global Offering.</p>\n<p>2. Full exercise of the Over-allotment Option  \n   • On 30 June 2026, the Sole Sponsor-Overall Coordinator fully exercised the Over-allotment Option for the same 2.13 million H Shares.  \n   • The shares were issued at the Offer Price of HK$96.06 per H Share, excluding related transaction costs (1.00% brokerage, 0.0027% SFC levy, 0.00565% Stock Exchange fee, and 0.00015% AFRC levy).  \n   • The issuance facilitated timely delivery to investors who had agreed to delayed settlement under the Global Offering.</p>\n<p>No market purchases or sales of LongBio’s H Shares were conducted for stabilization purposes during the period.</p>\n<p>The company’s board, chaired by Executive Director Dr. Liu Heng, confirmed that the stabilization measures have now concluded.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01779","symbol_name":"天辰生物-B","start_time":0,"source_url":"","article_id":"1189095400","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189095400","pubTimestamp":1782989108,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"LongBio Pharma (Suzhou) Co., Ltd. (LONGBIO-B) announced the completion of the 30-day post-listing stabilization period for its Global Offering, which concluded on 2 July 2026. During this window,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01779":"天辰生物-B"},"translate_title":"龙生物结束企稳；超额配股权以96.06港元全数行使213万股H股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01779":1},"content_text":"LongBio Pharma (Suzhou) Co., Ltd. (LONGBIO-B) announced the completion of the 30-day post-listing stabilization period for its Global Offering, which concluded on 2 July 2026. During this window, Sinolink Securities (Hong Kong) Company Limited, acting as Stabilizing Manager, executed two key actions:\n1. Overallocation  \n   • 2.13 million H Shares were over-allocated in the International Offering, equivalent to approximately 15% of the 14.19 million Offer Shares initially available under the Global Offering.\n2. Full exercise of the Over-allotment Option  \n   • On 30 June 2026, the Sole Sponsor-Overall Coordinator fully exercised the Over-allotment Option for the same 2.13 million H Shares.  \n   • The shares were issued at the Offer Price of HK$96.06 per H Share, excluding related transaction costs (1.00% brokerage, 0.0027% SFC levy, 0.00565% Stock Exchange fee, and 0.00015% AFRC levy).  \n   • The issuance facilitated timely delivery to investors who had agreed to delayed settlement under the Global Offering.\nNo market purchases or sales of LongBio’s H Shares were conducted for stabilization purposes during the period.\nThe company’s board, chaired by Executive Director Dr. Liu Heng, confirmed that the stabilization measures have now concluded.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189095400","isCrawlerRequest":true}